X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (329) 329
oncology (275) 275
female (265) 265
male (258) 258
middle aged (251) 251
index medicus (239) 239
aged (221) 221
adult (205) 205
chemotherapy (150) 150
lung neoplasms - drug therapy (142) 142
carcinoma, non-small-cell lung - drug therapy (126) 126
treatment outcome (109) 109
aged, 80 and over (107) 107
cancer (105) 105
lung neoplasms - pathology (105) 105
neoplasm staging (89) 89
antineoplastic combined chemotherapy protocols - therapeutic use (88) 88
respiratory system (88) 88
carcinoma, non-small-cell lung - pathology (79) 79
lung cancer, non-small cell (79) 79
retrospective studies (79) 79
prognosis (78) 78
gefitinib (76) 76
care and treatment (72) 72
disease-free survival (70) 70
survival (70) 70
lung neoplasms - mortality (66) 66
mutation (64) 64
non-small cell lung cancer (64) 64
carcinoma (60) 60
lung cancer (59) 59
antineoplastic agents - therapeutic use (57) 57
lung neoplasms - genetics (57) 57
survival rate (56) 56
carcinoma, non-small-cell lung - mortality (54) 54
erlotinib (53) 53
survival analysis (53) 53
analysis (51) 51
hematology, oncology and palliative medicine (49) 49
cisplatin (47) 47
adenocarcinoma (46) 46
medical colleges (46) 46
protein kinase inhibitors - therapeutic use (46) 46
therapy (46) 46
carcinoma, non-small-cell lung - genetics (44) 44
nsclc (42) 42
cisplatin - administration & dosage (41) 41
open-label (41) 41
research (41) 41
trial (41) 41
docetaxel (40) 40
tumors (40) 40
adenocarcinoma - drug therapy (39) 39
metastasis (37) 37
original (36) 36
antineoplastic combined chemotherapy protocols - adverse effects (35) 35
disease progression (34) 34
follow-up studies (34) 34
medicine & public health (34) 34
original article (33) 33
receptor, epidermal growth factor - genetics (33) 33
hematology (32) 32
pulmonary/respiratory (32) 32
expression (31) 31
kaplan-meier estimate (30) 30
quinazolines - therapeutic use (30) 30
radiotherapy (30) 30
adolescent (29) 29
growth-factor receptor (29) 29
multicenter (29) 29
mutations (29) 29
pharmacology & pharmacy (29) 29
prospective studies (29) 29
clinical trials (27) 27
epidermal growth factor (27) 27
gemcitabine (27) 27
surgery (27) 27
acquired-resistance (26) 26
patient outcomes (26) 26
young adult (26) 26
1st-line treatment (25) 25
adenocarcinoma - pathology (25) 25
animals (24) 24
cell lung-cancer (24) 24
epidermal growth factor receptor (24) 24
paclitaxel (24) 24
pemetrexed (24) 24
time factors (24) 24
egfr (23) 23
lung cancer, small cell (23) 23
non-small-cell lung cancer (23) 23
antineoplastic agents (22) 22
lung neoplasms - metabolism (22) 22
neoplasm metastasis (22) 22
patients (22) 22
receptor, epidermal growth factor - antagonists & inhibitors (22) 22
의약학 (22) 22
antimitotic agents (21) 21
lung neoplasms - diagnosis (21) 21
lung neoplasms - therapy (21) 21
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 7, pp. e268 - e269
Journal Article
Journal of Thoracic Oncology, ISSN 1556-0864, 01/2017, Volume 12, Issue 1, pp. S83 - S85
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 387, Issue 10030, pp. 1837 - 1846
Journal Article
Lancet, The, ISSN 0140-6736, 2016, Volume 389, Issue 10066, pp. 255 - 265
Journal Article
Lancet, The, ISSN 0140-6736, 2014, Volume 384, Issue 9944, pp. 665 - 673
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 5, pp. 577 - 589
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 7, pp. 763 - 774
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 5, pp. 528 - 538
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2012, Volume 13, Issue 1, pp. 33 - 42
Summary Background Findings from the phase 3 First-Line ErbituX in lung cancer (FLEX) study showed that the addition of cetuximab to first-line chemotherapy... 
Hematology, Oncology and Palliative Medicine | BREAST-CANCER | BIOMARKERS | GROWTH-FACTOR RECEPTOR | OVEREXPRESSION | ONCOLOGY | PROTEIN EXPRESSION | IN-SITU HYBRIDIZATION | CARCINOMAS | GENE AMPLIFICATION | ESTROGEN-RECEPTOR | III TRIAL | Immunohistochemistry | Lung Neoplasms - drug therapy | Up-Regulation | Prospective Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Lung Neoplasms - pathology | Male | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Patient Selection | Young Adult | Antibodies, Monoclonal, Humanized | Receptor, Epidermal Growth Factor - metabolism | Time Factors | Vinblastine - analogs & derivatives | Aged, 80 and over | Biomarkers, Tumor - metabolism | Brazil | Adult | Female | Biomarkers, Tumor - antagonists & inhibitors | Cetuximab | Odds Ratio | Republic of Korea | Carcinoma, Non-Small-Cell Lung - pathology | Lung Neoplasms - enzymology | Risk Assessment | Europe | Risk Factors | Kaplan-Meier Estimate | Proportional Hazards Models | Survival Rate | Treatment Outcome | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Carcinoma, Non-Small-Cell Lung - enzymology | Medical colleges | Care and treatment | Patient outcomes | Oncology, Experimental | Research | Lung cancer, Non-small cell | Antineoplastic agents | Antimitotic agents | Cancer patients | Chemotherapy | Product development | Tumors | Cancer
Journal Article
Lancet, The, ISSN 0140-6736, 2009, Volume 373, Issue 9674, pp. 1525 - 1531
Summary Background Use of cetuximab, a monoclonal antibody targeting the epidermal growth factor receptor (EGFR), has the potential to increase survival in... 
Internal Medicine | GROWTH-FACTOR RECEPTOR | 1ST-LINE TREATMENT | MEDICINE, GENERAL & INTERNAL | CARBOPLATIN | GEFITINIB | THERAPY | CISPLATIN | COMBINATION | GEMCITABINE | ERLOTINIB | PACLITAXEL | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptor, Epidermal Growth Factor - drug effects | Antibodies, Monoclonal - therapeutic use | Lung Neoplasms - pathology | Male | Antineoplastic Agents - therapeutic use | Vinblastine - administration & dosage | Cisplatin - administration & dosage | Young Adult | Antibodies, Monoclonal, Humanized | Vinblastine - analogs & derivatives | Aged, 80 and over | Adult | Female | Cetuximab | Carcinoma, Non-Small-Cell Lung - pathology | Proportional Hazards Models | Survival Rate | Treatment Outcome | Receptor, Epidermal Growth Factor - analysis | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Adolescent | Survival Analysis | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Neoplasm Staging | Chemotherapy | Research | Comparative analysis | Lung cancer, Non-small cell | Drug therapy | Health aspects | Cancer | Drugs | Studies | Data analysis | Lung cancer | Acne | Monoclonal antibodies | Clinical medicine | Kinases | Quality of life | Index Medicus | Abridged Index Medicus
Journal Article